Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DHODH | Q02127 | 1/20 | 0.49 |
| ▸ | PLG | P00747 | 1/20 | 0.48 |
| ▸ | PLAU | P00749 | 1/20 | 0.48 |
| ▸ | PLAT | P00750 | 1/20 | 0.48 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.46 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.46 |
| ▸ | SCN5A | Q14524 | 1/20 | 0.45 |
| ▸ | SCN9A | Q15858 | 1/20 | 0.45 |
| ▸ | MAP2K4 | P45985 | 1/20 | 0.44 |
| ▸ | P2RY14 | Q15391 | 6/20 | 0.44 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.44 |
| ▸ | CHEK2 | O96017 | 1/20 | 0.44 |
| ▸ | JAK2 | O60674 | 1/20 | 0.44 |
| ▸ | JAK1 | P23458 | 1/20 | 0.44 |
| ▸ | TYK2 | P29597 | 1/20 | 0.44 |
| ▸ | JAK3 | P52333 | 1/20 | 0.44 |
| ▸ | PDPK1 | O15530 | 1/20 | 0.42 |
| ▸ | MAP4K4 | O95819 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30787090 | 0.91 | DHODH (0.44) | DHODHPLGPLAUPLATHDAC8 | |
| SCHEMBL22570620 | 0.88 | P2RY14 (0.54) | P2RY14SLC6A2 | |
| SCHEMBL30290120 | 0.88 | P2RY14 (0.54) | P2RY14SLC6A2 | |
| SCHEMBL23796388 | 0.86 | HDAC8 (0.46) | HDAC8HDAC6SCN5ASCN9AP2RY14 | |
| SCHEMBL989175 | 0.85 | HDAC8 (0.47) | HDAC8HDAC6 | |
| SCHEMBL23796062 | 0.82 | SCN9A (0.50) | PLGPLAUPLATHDAC8HDAC6 | |
| SCHEMBL23796055 | 0.81 | NPSR1 (0.44) | PLGPLAUPLATHDAC8HDAC6 | |
| SCHEMBL23795946 | 0.81 | NPSR1 (0.44) | PLGPLAUPLATHDAC8HDAC6 | |
| SCHEMBL28620540 | 0.81 | NPSR1 (0.44) | PLGPLAUPLATHDAC8HDAC6 | |
| SCHEMBL23796037 | 0.81 | HDAC8 (0.47) | HDAC8HDAC6SCN5ASCN9AP2RY14 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240374571-A1 | PHARMACEUTICAL COMBINATIONS COMPRISING A TEAD INHIBITOR AND USES THEREOF FOR THE TREATMENT OF CANCERS | NOVARTIS AG (CH) | 2024-11-14 | — | — | US | disclosed |
| WO-2024176130-A1 | TEAD- AND HER2-INHIBITOR COMBINATIONS FOR TREATING CANCER | NOVARTIS AG (CH) | 2024-08-29 | — | — | WO | disclosed |
| EP-4395769-A1 | PHARMACEUTICAL COMBINATIONS COMPRISING A TEAD INHIBITOR AND USES THEREOF FOR THE TREATMENT OF CANCERS | Novartis AG (CH) | 2024-07-10 | — | — | EP | disclosed |
| CN-117835978-A | Pharmaceutical combinations comprising TEAD inhibitors and their use for cancer treatment | 诺华股份有限公司 | 2024-04-05 | — | — | CN | disclosed |
| US-11866431-B2 | Bicyclic compounds | VIVACE THERAPEUTICS, INC. (US) | 2024-01-09 | — | — | US | disclosed |
| WO-2023154811-A2 | TRANSCRIPTIONAL ENHANCED ASSOCIATE DOMAIN (TEAD) DEGRADERS AND USES THEREOF | THE BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIVERSITY (US) | 2023-08-17 | — | — | WO | disclosed |
| WO-2023031781-A1 | PHARMACEUTICAL COMBINATIONS COMPRISING A TEAD INHIBITOR AND USES THEREOF FOR THE TREATMENT OF CANCERS | NOVARTIS AG (CH) | 2023-03-09 | — | — | WO | disclosed |
| US-20230061429-A1 | BICYCLIC COMPOUNDS | VIVACE THERAPEUTICS, INC. | 2023-03-02 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11866431-B2 | Bicyclic compounds | YAP1, MYC, TEAD2 | DHODH 2769/4885PLG 3757/4885PLAU 3907/4885 |
| US-20240374571-A1 | PHARMACEUTICAL COMBINATIONS COMPRISING A TEAD INHIBITOR AND USES THEREOF FOR THE TREATMENT OF CANCERS | TP53, TEAD2, SERPINB1 | DHODH 289/4885PLG 644/4885PLAU 92/4885 |
| US-20230061429-A1 | BICYCLIC COMPOUNDS | YAP1, MYC, TEAD2 | DHODH 2769/4885PLG 3757/4885PLAU 3907/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.